ArticleCancer medicine2025
Incidence, Mortality and Survival Time Trends of Brain and CNS Tumours in the Canton of Zurich (Switzerland) Between 1980 and 2021.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to analyse trends in incidence, mortality and 5-year relative survival of malignant and benign/borderline brain and central nervous system (CNS) tumours between 1980 and 2021 in the Canton of Zurich, Switzerland, stratified by sex, age group, behaviour and histological subtypes.
methodsWe used incidence data from the Cancer Registry of Zurich, Zug, Schaffhausen and Schwyz, including primary benign/borderline and malignant tumours diagnosed between 1980 and 2021 in the Canton of Zurich in patients aged ≥ 15 years (N = 10,226). Mortality data were provided by the Swiss Federal Statistical Office (N = 3514). We calculated age-standardised incidence and mortality rates per 100,000 person-years and used Joinpoint to analyse trends.
resultsThe age-standardised incidence rate of malignant tumours was stable over time (around 7.7-8.2 per 100,000 person-years in men and 4.6-5.2 in women), while the rate of benign/borderline tumours increased from 3.8 in 1980-1990 to 10.8 in 2011-2021 in men and from 5.7 to 19.1 in women. The age-standardised mortality rate remained stable over time for malignant tumours (around 5.5-6.1 in men and 3.5-4.0 in women) but significantly decreased for benign/borderline tumours (from 1.0 to 0.5 in men and from 1.2 to 0.5 in women). Age-standardised 5-year relative survival increased from around 80% in 1980-1989 up to > 90% in 2011-2017 for benign/borderline tumours and from < 20% to around 30% for malignant tumours. There was a small survival advantage in women compared to men.
conclusionsWe observed an increase in incidence and a decrease in mortality rates for benign/borderline tumours, while both rates remained stable for malignant tumours. Five-year relative survival improved over time. The increasing incidence rates in benign/borderline tumours may be due to improved diagnostic techniques and an increasing use of CT scans, as reported in other countries. The increase in relative survival may reflect earlier detection and better treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.